Trial Profile
Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma (UC) and the impact of PI3K-mTOR pathway genomic alterations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary)
- Indications Carcinoma; Urogenital cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 22 Jul 2022 Status changed from recruiting to completed.
- 14 Feb 2018 New trial record